Beneficial Effects of Fluvoxamine for Chorea in a Patient With Huntington’s Disease

Albayrak, Yakup; Uğurlu, Görkem Karakaş; Uğurlu, Mustafa; Çayköylü, Ali

doi:10.4088/pcc.12l01369

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluvoxamine was reported to be effective for treating both hemiballism and depression in a patient with depressive disorder, and it was suggested that fluvoxamine might act as reducer of dopamine in striatal area 19. Fluvoxamine was also found to be beneficial for reducing choreic movements in a patient with Huntington's Disease 20. We reported that fluvoxamine was effective in the treatment of duloxetine induced TD 21.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

Albayrak

Hashimoto

2013

Psychiatry Investig

Self Cite

View full text Add to dashboard Cite

Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.

show abstract

Section: Discussionmentioning

confidence: 90%

“…19 Fluvoxamine was also found to be beneficial for reducing choreic movements in a patient with Huntington's Disease. 20 We reported that fluvoxamine was effective in the treatment of duloxetine induced TD. 21 Recently, we reported five patients with postpsychotic depression of schizophrenia who benefited from fluvoxamine in terms of TD.…”

Section: Discussionmentioning

confidence: 98%

Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

Albayrak

Hashimoto

2013

Psychiatry Investig

Self Cite

View full text Add to dashboard Cite

show abstract

“…They firstly concluded that the action mechanism of fluvoxamine for resolving akathisia might be associated with sigma 1 receptor agonism. We have also reported cases who benefited from fluvoxamine in terms of; hemiballism and depressive disorder27); tardive dyskinesia in patients with post-psychotic depressive disorder of schizophrenia28); duloxetine induced tardive dyskinesia29); tardive dyskinesia in two patients with schizophrenia30); tardive akathisia in a patient with schizophrenia30); and improvement of chorea 31). There are conflicting data on the activity of sigma 1 receptors on the dopaminergic system.…”

Section: Discussionmentioning

confidence: 99%

A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine

Albayrak

Beyazyüz

Abbak

et al. 2019

Clin Psychopharmacol Neurosci

Self Cite

View full text Add to dashboard Cite

Rabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of selective serotonin reuptake inhibitors and it is a potent agonist of sigma 1 receptors. In this article, we report a Rabbit Syndrome case who has benefited from fluvoxamine, in terms of both depressive disorder and Rabbit Syndrome; and present the data on the effects of sigma 1 agonist fluvoxamine on numerous movement disorders.

show abstract